ACE研究将指导心血管疾病全面防治的新策略精选.pptVIP

Rationale for ACE Trial Accumulating evidence suggests there is a close association between “prediabetes” and cardiovascular disease (CVD) Treating conventional risk factors in type 2 diabetes does not reduce CVD risk to the same level as in a non-diabetic population Post prandial hyperglycaemia may explain the excess risk seen in diabetes and “prediabetes” Acarbose has been reported* to reduce CVD risk in individuals with “prediabetes”, but its impact on new CVD events in individuals with “prediabetes” and existing CVD and is unknown ACE Trial Management Study Design Double-blind, multi-centre, randomised, controlled, clinical outcome trial comparing acarbose versus placebo Investigator designed and led academic trial Independent data collection, analysis and reporting Conducted in Mainland China and Hong Kong 7,500 patients in ~150 cardiovascular centres Minimum patient follow up four years Event driven (904 adjudicated primary events) ACE Steering Committee Major Inclusion Criteria Major Exclusion Criteria ACE Primary Endpoint ACE Secondary Endpoint Other Secondary Outcomes Sample Size Estimation Double Blind Intervention ACE Study Flow Chart Optimisation of Cardiovascular Therapy Safety Schedule How to Apply to be Part of the ACE Trial Apply Online at: www.dtu.ox.ac.uk/ACE * Professor Rury Holman University of Oxford, UK Professor Chang Yu Pan Professor Da Yi Hu Chinese PLA General Hospital University of Peking China China * Chiasson JL et al. JAMA 2003; 290(4): 486-94 Coordinating Centre Diabetes Trials Unit, University of Oxford ACE Chinese Project Office Oxford University (Beijing) Science Technology Limited Funding Study Medication Bayer HealthCare China Bayer Schering Pharma Rury Holman UK Diabetologist (Chair) DaYi Hu China Cardiologist (Co-Chair) ChangYu Pan China Diabetologist (Co-Chair) JiaLun Chen China Diabetologist (Honoured adviser) Juliana Chan Hong Kong Diabetologist Jean-Louis Chiasson Canada Diabetologist JunBo Ge China Cardiol